Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock
NASDAQ · ARTV
6.93
Fundamentals
Market cap
$341.74M
Price / Earnings ratio
-4.0x
Price / Sales ratio
N/A
Price / Book ratio
1.1x
Return on assets
-63.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
NeutralARTVJuly 8, 2026
Zacks Investment ResearchNeutral
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
ARTV

Stocktwits
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
NeutralARTVMay 8, 2026
StocktwitsNeutral
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
ARTV
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
157M104M52M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-83.9M
Net incomeEarnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news

Zacks Investment Research
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
NeutralARTVJuly 8, 2026
Zacks Investment ResearchNeutral
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
ARTV

Stocktwits
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
NeutralARTVMay 8, 2026
StocktwitsNeutral
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
ARTV
About Artiva Biotherapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees115
CEODr. Fred Aslan M.D.
IPO DateJul 19, 2024
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Fred Aslan M.D. | CEO, Principal Financial & Accounting Officer and Director | 1975 |
| Dr. Gines Diego Miralles M.D. | President and Head of Research & Development | 1963 |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Chief Operating Officer | 1975 |
| Mr. Christopher P. Horan | Chief Technical Operations Officer | 1967 |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor | 1974 |
| Mr. Andrew Cronauer | VP, General Counsel & Corporate Secretary | — |
| Dr. Nicholas Veomett Ph.D. | Vice President of Corporate Development | — |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development | 1965 |
| Dr. David Moriarty Ph.D. | Senior VP of Clinical Operations | — |
| Mr. Benjamin Dewees | Senior Vice President of Regulatory Affairs | — |
Fundamentals
Valuation
Market cap$341.74M
Price-to-sales ratioN/A
Price-to-book value1.05
Price-earnings ratio-4.00
Return on Equity-73.00%
Return on SalesN/A
Return on Assets-63.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.30
Income Statement
Average volume433,742
EBITDA$-84.44M
1 year high (52w)$14.53
1 year low (52w)$2.71
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -1.7 | -0.4 | +40.3 | -34.2 | +19.2 | -20.9 | ||||||
| 2025 | -49.0 | -15.1 | -23.5 | -20.3 | -18.6 | -22.2 | +96.1 | +11.3 | -7.1 | +42.8 | -0.3 | +23.6 |
| 2026 | -8.0 | +39.2 | +11.6 | +51.7 | -26.6 | +30.0 | +3.1 | +5.0 | -38.0 |



